DelveInsight has launched a new report on “Diffuse Large B-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s ” Diffuse Large B-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts:

• The total incident cases of DLBCL in the 7MM was assessed to be 67,743 in 2017, and are expected to increase during the study period (2017-2030).
• It was observed that the age-group with the highest incidence among the 7MM was 65 74 years in 2017. Patients of age group 5564 years were observed to be the second-highest in 2017.
• Among the EU5 countries, Germany had the highest incident population of DLBCL with 7,443 cases, followed by the United Kingdom and France, while Spain had the lowest incident cases in 2017.
• Japan had 9,485 cases for DLBCL in 2017, which accounted for nearly 14% of the total 7MM patient population of DLBCL.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Scope of the Report:

• Diffuse Large B-cell Lymphoma market report provides an in-depth analysis of Diffuse Large B-cell Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
• The Diffuse Large B-cell Lymphoma market report will help in developing business strategies by understanding the Diffuse Large B-cell Lymphoma Market trends & developments, key players and future market competition that will shape and drive the Diffuse Large B-cell Lymphoma market in the upcoming years.
• The Diffuse Large B-cell Lymphoma market report covers Diffuse Large B-cell Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
• The report provides a detailed assessment of the Diffuse Large B-cell Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.

 

Key Companies Covered:

• MorphoSys
• ADC Therapeutics
• Cellectar
• Karyopharm Therapeutics
• And Many others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Diffuse Large B-cell Lymphoma (DLBCL)is “a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte.”

DLBCL is a heterogeneous entity that includes a number of different variants and subtypes, with the current interest in identifying additional prognostically meaningful subsets. It occurs in young adults around age 35 and it affects slightly more women than men.

Diffuse large B-cell lymphoma grows rapidly in the lymph nodes and frequently involves the spleen, liver, bone marrow or other organs. Usually, DLBCL development starts in lymph nodes in the neck or abdomen and is characterized by masses of large B cells.

The most common symptom is painless swelling in the neck, armpit or groin. Other symptoms may include:.

• Tiredness
• Weight loss
• Night sweats
• High temperatures (fevers).

In 2016’s WHO updated classification, DLBCL is divided in to following entities, DLBCL, NOS (not otherwise specified); DLBCL subtypes (such as, T-cell/histiocyte-rich Large B-cell Lymphoma; Primary DLBCL of the central nervous system; Primary cutaneous DLBCL, leg type; EBV positive DLBCL, NOS) and Other lymphomas of large B-cells.

According to the Lymphoma Research Foundation, the occurrence of DLBCL generally increases with age, and most patients are over the age of 60 at diagnosis. It is more prevalent in male as compared to female.

 

Drugs Covered:

• MOR208
• ADCT-402
• CLR 131
• Selinexor
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Diffuse Large B-cell Lymphoma

3. Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma

4. Diffuse Large B-cell Lymphoma: Market Overview at a Glance

4.1. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2017

4.2. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2030

5. Diffuse Large B-cell Lymphoma: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Diffuse Large B-cell Lymphoma Treatment and Management

8.2. Diffuse Large B-cell Lymphoma Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Diffuse Large B-cell Lymphoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Diffuse Large B-cell Lymphoma Market Size in 7MM

13.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Diffuse Large B-cell Lymphoma Total Market Size in the United States

15.1.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Diffuse Large B-cell Lymphoma Total Market Size in Germany

15.3.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Diffuse Large B-cell Lymphoma Total Market Size in France

15.4.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Diffuse Large B-cell Lymphoma Total Market Size in Italy

15.5.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Diffuse Large B-cell Lymphoma Total Market Size in Spain

15.6.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Diffuse Large B-cell Lymphoma Total Market Size in the United Kingdom

15.7.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Diffuse Large B-cell Lymphoma Total Market Size in Japan

15.8.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market